The new diabetes drug Onglyza has no effect, good or bad, on a patient's risk for heart attacks, a new study finds. However, the researchers did find a surprising rise in hospitalizations for heart failure among those who took the medication compared to those who did not. Deepak Bhatt, HMS professor of medicine at Brigham and Women’s Hospital, is the co-principal investigator. Eugene Braunwald, the Hersey Distinguished Professor of the Theory and Practice of Physic at HMS, is the study chairman.
News & Research
